US Bancorp’s Astria Therapeutics ATXS Stock Holding History

US Bancorp’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70	Closed	-$916	–	4173
2025 Q4	$916	Buy	+70	New	+$836	﹤0.01%	3867

US Bancorp's ATXS Position: Q1 2026 in Review

US Bancorp sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 70 shares — an estimated $916 sold.

US Bancorp first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $916 in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

US Bancorp reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
US Bancorp sold 70 Astria Therapeutics shares in Q1 2026, an estimated $916.
US Bancorp first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
US Bancorp's Astria Therapeutics position peaked at $916 in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.